Skip to main
ARVN

Arvinas Inc (ARVN) Stock Forecast & Price Target

Arvinas Inc (ARVN) Analyst Ratings

Based on 19 analyst ratings
Buy
Strong Buy 37%
Buy 32%
Hold 26%
Sell 0%
Strong Sell 5%

Bulls say

Arvinas Inc. is advancing its pipeline of innovative therapies, particularly highlighting the potential of ARV-806, which has exhibited over 40 times greater potency in reducing KRAS G12D protein compared to existing clinical degraders, positioning it advantageously in the competitive landscape. The company’s proprietary PROTAC technology showcases significant improvements in both efficacy and safety profiles, evidenced by favorable results in larger patient populations compared to comparable therapies. Additionally, the ability of certain candidates to synergize with PD-1 blockade and promote immune memory indicates promising potential for enhanced antitumor immunity, which may lead to successful clinical outcomes and bolster the company's long-term growth trajectory.

Bears say

Arvinas Inc's financial outlook appears negative primarily due to significant revenue reductions projected for its product vepdeg, which has been downgraded to a peak revenue estimate of $296.9 million by 2035, substantially lower than the previously anticipated $641.2 million. Additionally, the company's inability to access capital may hinder critical operations, potentially delaying profitability and cash flow generation. Moreover, recent data indicates a decline in the overall response rate for their therapy candidates in pancreatic cancer, which could undermine market confidence and negatively impact financial performance.

Arvinas Inc (ARVN) has been analyzed by 19 analysts, with a consensus rating of Buy. 37% of analysts recommend a Strong Buy, 32% recommend Buy, 26% suggest Holding, 0% advise Selling, and 5% predict a Strong Sell.

This aggregate rating is based on analysts' research of Arvinas Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Arvinas Inc (ARVN) Forecast

Analysts have given Arvinas Inc (ARVN) a Buy based on their latest research and market trends.

According to 19 analysts, Arvinas Inc (ARVN) has a Buy consensus rating as of Jan 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17.79, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17.79, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Arvinas Inc (ARVN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.